Clinical Trial

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 3, 2024 (before its estimated October 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this observational study is to evaluate the safety and efficacy of camrelizumab and apatinib in patients with advanced gastric cancer under real-life conditions, particularly in various subgroups of gastric cancer patients, with a view to providing information about the treatment modalities and efficacy of the treatment in real-life gastric cancer patients and to explore the possible predictive biomarkers of prognosis.Patients, who had both decided to be treated with camrelizumab or apatinib prior to enrollment, were entered into one of the following three cohorts at the discretion of the investigator, based on their disease stage and prior treatment
Trial Details
NCT Number NCT06485271
Lead Sponsor Changzhi People's Hospital Affiliated to Changzhi Medical College
Conditions Gastric Cancer, RWS, PD-1 Immunotherapy
Enrollment 504 participants
Start Date 2023-11-01
Primary Completion 2025-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2024-07-03